每周股票复盘：复旦张江（688505）研发投入大增，泰州基地助力ADC药物研发

Group 1 - The core stock price of Fudan Zhangjiang (688505) closed at 8.11 yuan, up 0.12% from the previous week, with a market cap of 8.583 billion yuan [1] - The company ranks 52 out of 152 in the chemical pharmaceutical sector and 1803 out of 5140 in the A-share market [1] - The company actively communicates with investors through various platforms to ensure transparency and timely disclosure of business progress [1][3] Group 2 - Fudan Zhangjiang focuses on innovative research and development in biomedicine, establishing multiple technology platforms including photodynamic technology and ADC drug development [1][3] - R&D expenses increased by approximately 70 million yuan compared to the same period last year, with several ADC drug projects entering clinical stages [1][3] - The FDA018 antibody-drug conjugate project has entered phase III clinical trials, while the FZ-AD005 antibody-drug conjugate project has entered phase I clinical trials [1] Group 3 - The company has entered into a structured deposit agreement with Shanghai Pudong Development Bank, investing a total of 220 million yuan [2][3] - The structured deposit product has a low-risk rating, with a term of 89 days and an expected annualized return of 0.85%-2.40% [2]